Several experimental evidences highlighted that the upregulation of hypoxia-inducible factor 1 α (HIF-1α) supports LSCs maintenance and potency [4–7], thus indicating that the identification of new drugs targeting HIF-1α may be crucial for developing combined therapeutic strategies to effectively treat patients with CML. The gene discussed is HIF1A; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.